Evorpacept + Trastuzumab + Chemotherapy (ASPEN-09)

About ALX Oncology

ALX Oncology is dedicated to expanding treatment possibilities for cancer patients by developing synergistic approaches to optimize current and future standards of care. The company's core strategy revolves around its lead asset, evorpacept (ALX148), a next-generation CD47 inhibitor engineered to enhance anti-tumor activity of antibody-based therapies while minimizing hematologic toxicity. With a robust clinical pipeline spanning multiple high-value oncology indications and strategic partnerships with major pharmaceutical companies, ALX is positioned to advance the next generation of combination cancer treatments.

Therapeutic Areas